SCH 434: A new antihistamine-decongestant for seasonal allergic rhinitis
In a double-blind, multicenter study, we compared the effects of SCH 434 (Claritin-D; Schering Corp., Kenilworth, N.J.), a new sustained-release, combination antihistamine-decongestant medication, with the effects of its individual components and placebo in 435 patients with seasonal allergic rhinit...
Gespeichert in:
| Veröffentlicht in: | Journal of allergy and clinical immunology 1989-01, Vol.93 (6), p.1083-1090 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1090 |
|---|---|
| container_issue | 6 |
| container_start_page | 1083 |
| container_title | Journal of allergy and clinical immunology |
| container_volume | 93 |
| creator | Storms, W W Bodman, S F Nathan, R A Chervinsky, P Banov, CH Dockhorn, R J Jarmoszuk, I Zeitz, HJ McGeady, S J |
| description | In a double-blind, multicenter study, we compared the effects of SCH 434 (Claritin-D; Schering Corp., Kenilworth, N.J.), a new sustained-release, combination antihistamine-decongestant medication, with the effects of its individual components and placebo in 435 patients with seasonal allergic rhinitis. SCH 434 contains 5 mg of loratadine, a nonsedating antihistamine, and 120 mg of pseudoephedrine as the decongestant component. All treatments were safe and well tolerated, although insomnia and dry mouth were noted in a significant number of patients who received either SCH 434 or pseudoephedrine. No serious side effects were noted. The incidence of sedation did not differ significantly among the four treatment groups. The authors conclude that SCH 434 is a safe and effective treatment for symptoms of seasonal allergic rhinitis. The combination drug (SCH 434) was better than its components for some, but not all, symptoms. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_15278632</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>15278632</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_152786323</originalsourceid><addsrcrecordid>eNqNjLsOgkAQAK_QRHz8w1Z2JMAhDztDNPTamwsusObY01uIvy-FH2A1mWQyCxVEURmHWZ6WK7UWeUaz66IMVH2takh1eoQTMH7A8Eg9yWgGYgwf2DjucFYeoXUeBI04NhaMteg7asD3xDSSbNWyNVZw9-NG7S_nW1WHL-_e07y4DyQNWmsY3ST3-JDkRaYT_Xf4BdzEPf4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15278632</pqid></control><display><type>article</type><title>SCH 434: A new antihistamine-decongestant for seasonal allergic rhinitis</title><source>Elsevier ScienceDirect Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Storms, W W ; Bodman, S F ; Nathan, R A ; Chervinsky, P ; Banov, CH ; Dockhorn, R J ; Jarmoszuk, I ; Zeitz, HJ ; McGeady, S J</creator><creatorcontrib>Storms, W W ; Bodman, S F ; Nathan, R A ; Chervinsky, P ; Banov, CH ; Dockhorn, R J ; Jarmoszuk, I ; Zeitz, HJ ; McGeady, S J</creatorcontrib><description>In a double-blind, multicenter study, we compared the effects of SCH 434 (Claritin-D; Schering Corp., Kenilworth, N.J.), a new sustained-release, combination antihistamine-decongestant medication, with the effects of its individual components and placebo in 435 patients with seasonal allergic rhinitis. SCH 434 contains 5 mg of loratadine, a nonsedating antihistamine, and 120 mg of pseudoephedrine as the decongestant component. All treatments were safe and well tolerated, although insomnia and dry mouth were noted in a significant number of patients who received either SCH 434 or pseudoephedrine. No serious side effects were noted. The incidence of sedation did not differ significantly among the four treatment groups. The authors conclude that SCH 434 is a safe and effective treatment for symptoms of seasonal allergic rhinitis. The combination drug (SCH 434) was better than its components for some, but not all, symptoms.</description><identifier>ISSN: 0091-6749</identifier><language>eng</language><ispartof>Journal of allergy and clinical immunology, 1989-01, Vol.93 (6), p.1083-1090</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids></links><search><creatorcontrib>Storms, W W</creatorcontrib><creatorcontrib>Bodman, S F</creatorcontrib><creatorcontrib>Nathan, R A</creatorcontrib><creatorcontrib>Chervinsky, P</creatorcontrib><creatorcontrib>Banov, CH</creatorcontrib><creatorcontrib>Dockhorn, R J</creatorcontrib><creatorcontrib>Jarmoszuk, I</creatorcontrib><creatorcontrib>Zeitz, HJ</creatorcontrib><creatorcontrib>McGeady, S J</creatorcontrib><title>SCH 434: A new antihistamine-decongestant for seasonal allergic rhinitis</title><title>Journal of allergy and clinical immunology</title><description>In a double-blind, multicenter study, we compared the effects of SCH 434 (Claritin-D; Schering Corp., Kenilworth, N.J.), a new sustained-release, combination antihistamine-decongestant medication, with the effects of its individual components and placebo in 435 patients with seasonal allergic rhinitis. SCH 434 contains 5 mg of loratadine, a nonsedating antihistamine, and 120 mg of pseudoephedrine as the decongestant component. All treatments were safe and well tolerated, although insomnia and dry mouth were noted in a significant number of patients who received either SCH 434 or pseudoephedrine. No serious side effects were noted. The incidence of sedation did not differ significantly among the four treatment groups. The authors conclude that SCH 434 is a safe and effective treatment for symptoms of seasonal allergic rhinitis. The combination drug (SCH 434) was better than its components for some, but not all, symptoms.</description><issn>0091-6749</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><recordid>eNqNjLsOgkAQAK_QRHz8w1Z2JMAhDztDNPTamwsusObY01uIvy-FH2A1mWQyCxVEURmHWZ6WK7UWeUaz66IMVH2takh1eoQTMH7A8Eg9yWgGYgwf2DjucFYeoXUeBI04NhaMteg7asD3xDSSbNWyNVZw9-NG7S_nW1WHL-_e07y4DyQNWmsY3ST3-JDkRaYT_Xf4BdzEPf4</recordid><startdate>19890101</startdate><enddate>19890101</enddate><creator>Storms, W W</creator><creator>Bodman, S F</creator><creator>Nathan, R A</creator><creator>Chervinsky, P</creator><creator>Banov, CH</creator><creator>Dockhorn, R J</creator><creator>Jarmoszuk, I</creator><creator>Zeitz, HJ</creator><creator>McGeady, S J</creator><scope>7T2</scope><scope>7T5</scope><scope>7U2</scope><scope>C1K</scope><scope>H94</scope></search><sort><creationdate>19890101</creationdate><title>SCH 434: A new antihistamine-decongestant for seasonal allergic rhinitis</title><author>Storms, W W ; Bodman, S F ; Nathan, R A ; Chervinsky, P ; Banov, CH ; Dockhorn, R J ; Jarmoszuk, I ; Zeitz, HJ ; McGeady, S J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_152786323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Storms, W W</creatorcontrib><creatorcontrib>Bodman, S F</creatorcontrib><creatorcontrib>Nathan, R A</creatorcontrib><creatorcontrib>Chervinsky, P</creatorcontrib><creatorcontrib>Banov, CH</creatorcontrib><creatorcontrib>Dockhorn, R J</creatorcontrib><creatorcontrib>Jarmoszuk, I</creatorcontrib><creatorcontrib>Zeitz, HJ</creatorcontrib><creatorcontrib>McGeady, S J</creatorcontrib><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Journal of allergy and clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Storms, W W</au><au>Bodman, S F</au><au>Nathan, R A</au><au>Chervinsky, P</au><au>Banov, CH</au><au>Dockhorn, R J</au><au>Jarmoszuk, I</au><au>Zeitz, HJ</au><au>McGeady, S J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SCH 434: A new antihistamine-decongestant for seasonal allergic rhinitis</atitle><jtitle>Journal of allergy and clinical immunology</jtitle><date>1989-01-01</date><risdate>1989</risdate><volume>93</volume><issue>6</issue><spage>1083</spage><epage>1090</epage><pages>1083-1090</pages><issn>0091-6749</issn><abstract>In a double-blind, multicenter study, we compared the effects of SCH 434 (Claritin-D; Schering Corp., Kenilworth, N.J.), a new sustained-release, combination antihistamine-decongestant medication, with the effects of its individual components and placebo in 435 patients with seasonal allergic rhinitis. SCH 434 contains 5 mg of loratadine, a nonsedating antihistamine, and 120 mg of pseudoephedrine as the decongestant component. All treatments were safe and well tolerated, although insomnia and dry mouth were noted in a significant number of patients who received either SCH 434 or pseudoephedrine. No serious side effects were noted. The incidence of sedation did not differ significantly among the four treatment groups. The authors conclude that SCH 434 is a safe and effective treatment for symptoms of seasonal allergic rhinitis. The combination drug (SCH 434) was better than its components for some, but not all, symptoms.</abstract></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0091-6749 |
| ispartof | Journal of allergy and clinical immunology, 1989-01, Vol.93 (6), p.1083-1090 |
| issn | 0091-6749 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_15278632 |
| source | Elsevier ScienceDirect Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| title | SCH 434: A new antihistamine-decongestant for seasonal allergic rhinitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T10%3A02%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SCH%20434:%20A%20new%20antihistamine-decongestant%20for%20seasonal%20allergic%20rhinitis&rft.jtitle=Journal%20of%20allergy%20and%20clinical%20immunology&rft.au=Storms,%20W%20W&rft.date=1989-01-01&rft.volume=93&rft.issue=6&rft.spage=1083&rft.epage=1090&rft.pages=1083-1090&rft.issn=0091-6749&rft_id=info:doi/&rft_dat=%3Cproquest%3E15278632%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=15278632&rft_id=info:pmid/&rfr_iscdi=true |